Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

A highly collaborative investment professional and research analyst with 10+ years of international experience in equity research, treasury operations, and trading positions across multiple asset classes at leading multinational banks Citibank and Morgan Stanley, UHNWI-backed family office and European independent equity research firm. A respectable background in equity capital markets, corporate treasury, investment banking operations, equity research analysis and portfolio management.

2025 High Conviction: TransMedics, The Market Leader and Disruptor In Organ Transplant Therapy

Equity Bottom-Up

<ul>
<li>TransMedics Group stock surged ~20% on blowout 1Q’25 earnings on Friday after the company beat earnings expectations and hiked 2025 revenue guidance.</li>
<li>I launched coverage of the stock in November 2024 and added TransMedics Group to my high conviction list of ideas.</li>
<li>TransMedics Group shares have massively outperformed in 2025 with shares up ~79% over the year. I acknowledge limited upside and lower my PT to $118 on peer-group multiple compression.</li>
</ul>


TransMedics Group stock surged ~20% on blowout 1Q’25 earnings on Friday after the company beat earnings expectations and hiked 2025 revenue guidance.
I launched coverage of the stock in November 2024 and added TransMedics Group to my high conviction list of ideas.
TransMedics Group shares have massively outperformed in 2025 with shares up ~79% over the year. I acknowledge limited upside and lower my PT to $118 on peer-group multiple compression.


2025 High Conviction Update: TransMedics, Cut Long Exposure and Move To the Sidelines